BOSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in digital care, announced company leaders will participate in several upcoming investor conferences. Ido Schoenberg, M.D., Amwell chairman and chief executive officer, and Mark Hirschhorn, Amwell chief financial officer, will participate in fireside chats or one-on-one meetings at these events:
An audio webcast of the fireside chats will be available at investors.amwell.com.
About Amwell
Amwell is a leading hybrid care delivery enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. We offer a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the digital care of more than 50 health plans, which collectively represent more than 100 million covered lives, and many of the nation’s largest health systems. For more information, please visit https://business.amwell.com/.
©2024 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, Amwell Converge™, Carepoint™ and the Amwell Logo are registered trademarks of American Well Corporation.
Last Trade: | US$10.97 |
Daily Change: | 0.68 6.61 |
Daily Volume: | 38,601 |
Market Cap: | US$149.960M |
January 15, 2025 December 18, 2024 October 30, 2024 October 08, 2024 July 31, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load